In 2023, Johnson & Johnson announced it had stopped research and development on therapeutics for many infectious diseases, including hepatitis and tuberculosis. Less visibly, AbbVie shuttered last ...

AI will be a useful tool in reducing R&D costs to help alleviate some of the pain pharma will feel by the imminent patent cliff. Speaking at Arena International’s Clinical Data Management Innovation ...

While coming back down from 2023’s dizzying high, Merck & Co. still managed to hang on to the top spot of our annual R&D budgets in pharma list. Though Merck’s 2024 R&D spending plummeted by almost ...

It’s no surprise that pharma research and development (R&D) remains one of the most important hubs for innovation. Every pharma company invests heavily in and relies on R&D teams to create new ...

[Interpreted] [Operator Instructions] We'd like to start the presentation with Chris. We'd like to cover the business highlight, followed by Maeda to give the highlights of the Japanese business, and ...

AstraZeneca is paying CSPC Pharmaceutical Group $110 million up front to tap that China-based biotech’s artificial intelligence-driven technology for discovering and developing novel oral drugs. The R ...

Recent studies have highlighted increasing biomedical innovation originating from Asia—especially China—over the past decade 1. Research and development (R&D) partnerships and licensing transactions ...

DUBLIN--(BUSINESS WIRE)--The "Pharmaceutical R&D Outsourcing Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering. The Pharmaceutical R&D Outsourcing Market ...

The wait is over. Fierce Biotech has released its annual ranking of the top 10 pharma R&D budgets of 2025—offering a clear look at which companies are spending the most on innovation and how those ...